Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2545-2549

  Gomez Flores, Ricardo ^a,b   Hsia, Renee ^a   Tamez Guerra, Reyes ^b   Mehta, Reeta T ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMYRISTOYLPHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; RESORCINOMYCIN A;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

EID: 0029913531     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2545     Document Type: Article

References (32)

1. Ashtekar, D., N. Düzgünes, and P. R. J. Gangadharam. 1991. Activity of free and liposome encapsulated streptomycin against Mycobacterium avium complex (MAC) inside peritoneal macrophages. J. Antimicrob. Chemother. 28: 615-617.
2. Baron, E. J., and L. S. Young. 1986. Amikacin, ethambutol and rifampin for treatment of disseminated Mycobacterium avium intracellulare infections in patients with acquired immunodeficiency syndrome. Diagn. Microbiol. Infect. Dis. 5:215-220.
3. Bergers, J. J., T. L. Ten Hagen, E. W. Van Etten, and I. A. Bakker-Woudenberg. 1995. Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm. World Sci. 17:1-11.
4. Bermudez, L. E. 1994. Use of liposome preparation to treat mycobacterial infections. Immunobiology 191:578-583.
5. Bermudez, L. E. M., and L. S. Young. 1988. Tumor necrosis factor, alone or in combination with IL-2. but not IFN-γ, is associated with macrophage killing of Mycobacterium avium complex. J. Immunol. 140:3006-3013.
6. Bermudez, L. E. M., M. Wu, and L. S. Young. 1987. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J. Infect. Dis. 156:510-513.
7. Davidson, P. T., V. Khanijo, M. Goble, and T. S. Moulding. 1985. Treatment of disease due to Mycobacterium intracellulare. Rev. Infect. Dis. 3:1052-1059.
8. Desiderio, J. V., and S. G. Campbell. 1983. Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin. J. Infect. Dis. 148:563-570.
9. Douvas, G. S., M. H. May, E. Ross, and A. J. Crowle. 1992. Characterization of inhibition of Mycobacterium avium replication in macrophages by normal human serum. Infect. Immun. 60:345-352.
10. Düzgünes, N., D. R. Ashtekar, D. L. Flasher, N. Ghori, R. J. Debs, D. S. Friend, and P. R. J. Gangadharam. 1991. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J. Infect. Dis. 164:143-151.
11. Fountain, M. W., C. Dees, and R. D. Schultz. 1981. Enhanced intracellular killing of Staphylococcus aureus by canine monocytes treated with liposomes containing amikacin, gentamicin, kanamycin and tobramycin. Curr. Microbiol. 6:373-376.
12. Gangadharam, P. R. J., D. Ashtekar, N. Ghori, J. A. Goldstein, R. Debs, and N. Düzgünes. 1991. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J. Antimicrob. Chemother. 28:425-435.
13. Gangadharam, P. R. J., and P. F. Pratt. 1983. In vitro response of murine alveolar and peritoneal macrophages to Mycobacterium intracellulare. Am. Rev. Respir. Dis. 128:1044-1047.
14. Gomez-Flores, R., S. Gupta, R. Tamez-Guerra, and R. T. Mehta. 1995. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J. Clin. Microbiol. 33:1842-1846.
15. Gregoriadis, G., and A. T. Florence. 1993. Liposomes in drug delivery: clinical, diagnostic and ophthalmic potential. Drugs 45:15-28.
16. Heifets, L. 1988. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob. Agents Chemother. 32:1131-1136.
17. Horsburgh, J. C. R. 1991. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:1332-1338.
18. Iseman, M. D., R. F. Corpe, R. J. O'Brien, D. Y. Rosenwerg, and E. Wolinsky. 1985. Disease due to Mycobacterium avium-intracellulare. Chest 187:139S-149S.
19. Karlowsky, J. A., and G. G. Zhanel. 1992. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin. Infect. Dis. 15: 654-667.
20. Kesavalu, L., J. S. Goldstein, R. J. Debs, N. Düzgünes, and P. R. J. Gangadharam. 1990. Differential effects of free and liposome encapsulated amikacin on growth of M. avium complex in mouse peritoneal macrophages. Tubercle 71:215-217.
21. Kondo, E., T. Katayama, Y. Kawamura, Y. Yasuda, K. Matsumoto, K. Ishii, T. Tanimoto, H. Hinoo, T. Kato, H. Kyotani, and J. Shoji. 1989. Isolation and characterization of new antibiotics resorcinomycins A and B. J. Antibiot. 42:1-6.
22. Masaki, S., T. Konishi, N. Tsuji, and J. Shoji. 1989. New antibiotics, resorcinomycins A and B: antibacterial activity of resorcinomycin A against mycobacteria in vitro. J. Antibiot. 42:463-466.
23. Mauel, J. 1983. Mechanisms of intracellular microorganisms destruction. Bull. Eur. Physiopathol. Respir. 19:115-122.
24. Mehta, R. T. 1996. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob. Agents Chemother. 40:1893-1902.
25. Mehta, R. T., T. J. McQueen, A. Keyhani, and G. Lopez-Berestein. 1994. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy (Basel) 40:256-264.
26. Mehta, R. T., A. Keyhani, T. J. McQueen, B. Rosenbaum, K. V. Rolston, and J. J. Tarrand. 1993. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 37:2584-2587.
27. Mehta, R. T., K. Mehta, G. Lopez-Berestein, and R. L. Juliano. 1985. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect. Immun. 47:429-433.
28. Roerdink, F., J. Regts, T. Daemen, I. Bakker-Woudenberg, and G. Scherphof. 1986. Liposomes as drug carriers to liver macrophages: fundamental and therapeutic aspects, p. 193-206. In G. Gregoriadis, J. Senior, and G. Poste (ed.), Targeting of drugs with synthetic systems. Plenum Press, New York.
29. Stevenson, M., A. J. Baillie, and R. M. E. Richards. 1983. Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob. Agents Chemother. 24:742-749.
30. Tucker, S. D., M. R. Sivaramakrishnan, J. Klostergaard, and G. Lopez-Berestein. 1991. Independence of the pattern of early cytokine release from autoregulation by nitric oxide. J. Leukocyte Biol. 50:509-516.
31. Vistica, D. T., P. Skehan, D. Scudiero, A. Monks, A. Pittman, and M. R. Boyd. 1991. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 51:2515-2520.
32. Yui, S., and M. Yamazaki. 1991. Augmentation and suppression of release of tumor necrosis factor from macrophages by negatively charged phospholipids. Jpn. J. Cancer Res. 82:1028-1034.